On 28 May, ProMIS Neurosciences, a biotechnology company focused on the development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases such Alzheimer’s disease (AD) announced the identification of several antibody candidates that selectively bind the toxic form of the Tau protein – one of the hallmarks of AD. These novel antibodies join a pipeline of antibody candidates including lead product candidate PMN310 that selectively targets the toxic form of the amyloid beta protein “The ProMIS platform addresses a problem that has plagued the Alzheimer’s drug development community: the inability to selectively target the neurotoxic form of Tau and amyloid beta,” said Dr. Neil Cashman, Chief Science Officer of ProMIS Neurosciences.
ProMIS Neurosciences identifies new antibody candidates for AD
28/05/2019
